Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
IntroductionEpilepsy poses significant management challenges, particularly in patients with refractory epilepsy where conventional antiseizure medications (ASMs) are ineffective. Cenobamate (CNB), a recently approved third-generation ASM, has shown unprecedented efficacy as an adjunctive therapy in...
Saved in:
| Main Authors: | Patrick M. House, Lars Wiese |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1558614/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom
by: Sylvain Rheims, et al.
Published: (2025-06-01) -
Increase of Brivaracetam serum concentration with introduction of Cenobamate
by: Lena Bender, et al.
Published: (2025-04-01) -
Early Introduction of Cenobamate in Uncontrolled Focal Epilepsy: Insights from a Structured Controversy
by: Angelo Labate, et al.
Published: (2025-06-01) -
Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox–Gastaut Syndrome: A Retrospective Chart Review
by: Karen Keough, et al.
Published: (2025-06-01) -
Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
by: Maria Luiza Giraldes de MANREZA, et al.
Published: (2021-06-01)